GENE ONLINE|News &
Opinion
Blog

CAR T-cell Therapy
Overcoming Immune Evasion in CAR-T Therapies with Groundbreaking New Discoveries
2022-09-22
Bristol Myers’ Breyanzi Now FDA-Approved for Earlier Lymphoma
2022-06-27
Bayer Terminates CAR T-Cell Deal With Atara After Patient Death
2022-05-20
AACR 2022: Stand Up to Cancer, Standing up to Treatment
2022-04-21
J&J, Legend’s Cell Therapy Gets FDA Nod
2022-03-01
AbClon, HK inno.N Collaborates to Take On Novartis’ CAR T-Cell Therapy
2022-02-15
Fujifilm Expands CDMO Operations by Buying Atara’s Cell Therapy Plant for $100 Million
2022-01-27
Bristol-Myers Squibb’s Abecma Becomes First Approved CAR T-Cell Therapy for Multiple Myeloma in Japan
2022-01-24
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
Daiichi Sankyo Authorizes First Yescarta Treatment Site in Japan
2021-12-17
ASH 2021: Understanding the Crosstalk between Acute Leukemia and Down Syndrome for Designing Better Therapies
2021-12-16
Considering Manufacturing and Commercial Advantages, Poseida Makes Strategic Shift Towards Allogeneic CAR-T Products
2021-11-10
Blackstone Chips in $250 Million to Aid Autolus’ CAR-T Therapy
2021-11-09
FDA Approves Kite’s CAR-T Therapy for Adult Leukemia
2021-10-04
Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?
2021-09-29
1 2 3 4
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!